Genmab — Juni 2020

Helge_LarsenPI-redaktør

Jeg har faktisk ikke oplevet hype nogen steder i forbindelse med stigningen i Genmab.

E_L

a bit more on Ofa - FDA delays decision on Novartis’ potential blockbuster MS drug, wiping away priority review - https://endpts.com/fda-delays-decision-on-novartiss-potential-blockbuster-ms-drug-wiping-away-priority-review/

Stockwatch1

Bryan Garnier cuts to Neutral from Buy, fair value 1950 vs 1900

Stockwatch1

In view of the current valuation, and even though fundamentals are strong and coming months will be rich with catalysts, we are downgrading our rating

Stockwatch1

We believe the market has already priced in most if not all positive developments. We also note though the 3-month delay in the approval of scofatumumab announced by Novartis yesterday

Stockwatch1

BioNTech collaboration adds DKK50/share to our Fair Value

E_L

H.C. Wainwright reiterates Buy on Genmab, says ofatumumab delay not impactful Genmab's (GMAB) partner Novartis (NVS) announced yesterday that the Prescription Drug User Fee Act approval decision date on ofatumumab for treatment of relapsing-remitting multiple sclerosis had been pushed back three months to September 20, H.C. Wainwright analyst Raghuram Selvaraju tells investors in a research note

E_L

Since the analyst always assumed that royalty-based revenues from ofatumumab sales in the U.S. would only begin accruing to Genmab starting in early 2021, he does not view the delay as impactful and is not making any changes to forecasts. Selvaraju, who notes that Novartis continues to expect ofatumumab approval for the MS indication in Europe during Q2 of 2021, reiterates a Buy rating on Genmab with a $34 price target.

The Fly | LANDINGPAGENEWS.PHP

Real-time market news, financial data, stock research, and portfolio tools from The Fly.

(thefly.com)

E_L

GOLDMAN SACHS belässt NOVARTIS AG auf 'Buy'
Die US-Investmentbank Goldman Sachs hat die Novartis-Aktie angesichts einer erweiterten US-Prüfung des Multiple-Sklerose-Medikaments Ofatumumab auf der "Conviction Buy List" mit einem Kursziel von 110 Franken belassen. Eine Verzögerung um drei Monate habe wohl keine bedeutende Auswirkungen auf den Kapitalwert des Pharmakonzerns, schrieb Analyst Keyur Parekh in einer am Mittwoch vorliegenden Studie.

Sukkeralf

Det er jo lidt biotek i en nøddeskal - de flyver op og ned alt efter "hypen"

Bulder

Lidt underligt, at der ikke medfølger en begrundelse for forsinkelsen. Covid19 f.eks.. Gør FDA's voucher system upålideligt.

Bulder

Iflg alt vi har set fra videskabsmænd er godkendelsen af ofa en no brainer. Så hvorfor?

Sukkeralf

I Endpoint artiklen antydes det måske, at det kan være inspektion af fabrik der er problemet - enten at den ikke har fundet sted eller at har været issues.

Bulder

Men FDA har da utvivlsomt begrundet det overfor Novartis. Har Novartis så noget at skjule?

Sukkeralf

Man er måske ikke interesseret i at vise sin "uduelighed", hvis det er Novartis´ egen fejl - slet ikke når man har brugt en priority voucher

Sukkeralf

Det er jo i princippet ret kikset, hvis det vitterlig er tilfældet

Bulder

Jeg har spurgt Andrew Carlsen om han ved noget.

Bulder

Han ved ikke noget. Var hurtigt tilbage.

AaBforever

Kursen på ADS følger 100%. $29,14 = 1936.

Stockwatch1

Et finanshus skriver: There is no reason in the press release that support the delay although there are usually two: either the agency is crowded by filings and cannot respect timelines due to the covid-19 crisis or Novartis has added new data in the course of the review and the agency is asking for more time to review the new data.